TearScience Secures $70 Million For One-Of-A-Kind Eye Device
This article was originally published in Start Up
Executive Summary
TearScience Inc. is ready to go into full-scale commercialization for a new device treatment for the most prevalent form of dry eye. In late February, the young company secured up to $70 million from HealthCare Royalty Partners to help make that happen.
You may also be interested in...
OrbiMed Launches $600M Royalty Fund
The diversified investment firm will aim for low-risk investments that bring faster returns to inventors, research institutions and smaller drug developers.
Texas To Tokyo: Japan Darvias Approval Marks End Of Long Development Road
Solasia's arsenical drug darinaparsin has received its global-first approval in Japan, for PTCL, in a landmark for the Texan chemist who discovered it back in the 70s and paving the way for wider indications and Asian markets.
US FDA Likely To Embrace In-Person, Remote Combo For Facility Inspections Going Forward
System likely will evolve as post-pandemic world unfolds, but adds to list of agency programs expecting to continue using virtual platforms once in-person activities are no longer restricted by COVID-19.